Top-News
Pharmazeutika USA

Histogen News

Aktie
WKN:  A3DMJS ISIN:  US43358Y2028 US-Symbol:  HSTO
0,20 $
+0,05 $
+33,33%
01.05.24 21:45:54
Handeln Depot/Watchlist
Aktienanzahl *
2,50 Mio.
Marktkapitalisierung *
466,83 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 07.06.2022

Histogen News

12.07.22 - PR Newswire
Thinking about buying stock in Histogen, Canoo, Aldeyra Therapeutics, Target Hospitality, or Redbox Entertainment?
Thinking about buying stock in Histogen, Canoo, Aldeyra Therapeutics, Target Hospitality, or Redbox Entertainment? PR Newswire
23.03.22 - PR Newswire
Thinking about buying stock in AMC Entertainment, Mullen Automotive, DiDi Global, Exela Technologies, or Histogen?
Thinking about buying stock in AMC Entertainment, Mullen Automotive, DiDi Global, Exela Technologies, or Histogen? PR Newswire
22.06.21 - PR Newswire
Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?
Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments? PR Newswire
07.01.21 - PR Newswire
DLA Piper advises Histogen in its US$14 million upsized public offering
DLA Piper advises Histogen in its US$14 million upsized public offering PR Newswire
06.02.20 - PR Newswire
Histogen to Present at BIO CEO & Investor Conference
Histogen to Present at BIO CEO & Investor Conference PR Newswire
30.01.20 - PR Newswire
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership Allergan Granted Exclusive Rights to Market Histogen's CCM in Dermabrasion Therapies PR ...
29.08.16 - PR Newswire
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH Company's non-​invasive ...
29.08.16 - PR Newswire
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH Company's non-​invasive ...

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »